CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)
CC-92480: an oral in vivo CRBN-based selective IKZF1/3 degrader
CC-92480
CRBN-based selective IKZF1/3 degrader oral efficacy in lenalidomide-resist. xenograft from phenotypic screen and optimization J. Med. Chem., Mar. 4, 2020 Celgene, San Diego, CA
Loading...
